Drug intelligence / Profile preview

HCW11-002

Development stage: Preclinical
Lead developer: HCW Biologics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

HCW11-002 is a recombinant fusion protein developed by HCW Biologics for the treatment of senescence-associated diseases and disorders of aging[5][9]. It was constructed using HCW Biologics' proprietary TRBC (T-cell Receptor β Chain constant region) platform technology[8]. The TRBC platform enables the creation of immunotherapeutics that can activate immune responses and target specific cells[8]. HCW11-002 is one of over 50 molecules constructed using this platform and has been selected as one of three lead candidates based on promising early preclinical data[8]. The drug is designed to address chronic inflammation, which is believed to be a significant contributing factor in many age-related diseases[8].

Beyond the preview

Go deeper on HCW11-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCW11-002.

Explore the full profile